不同原因血小板减少症患者促血小板生成素和血清白细胞介素-11水平的检测及意义

程旭, 潘湘涛, 王金湖, 等. 不同原因血小板减少症患者促血小板生成素和血清白细胞介素-11水平的检测及意义[J]. 临床血液学杂志, 2012, 25(3): 157-159. doi: 10.13201/j.issn.1004-2806.2012.02.008
引用本文: 程旭, 潘湘涛, 王金湖, 等. 不同原因血小板减少症患者促血小板生成素和血清白细胞介素-11水平的检测及意义[J]. 临床血液学杂志, 2012, 25(3): 157-159. doi: 10.13201/j.issn.1004-2806.2012.02.008
CHENG Xu, PAN Xiangtao, WANG Jinhu, et al. Measurement of serum thrombopoietin levels and serum interlukin-11 levels in patients with thrombocytopenia with different causes and its significance[J]. J Clin Hematol, 2012, 25(3): 157-159. doi: 10.13201/j.issn.1004-2806.2012.02.008
Citation: CHENG Xu, PAN Xiangtao, WANG Jinhu, et al. Measurement of serum thrombopoietin levels and serum interlukin-11 levels in patients with thrombocytopenia with different causes and its significance[J]. J Clin Hematol, 2012, 25(3): 157-159. doi: 10.13201/j.issn.1004-2806.2012.02.008

不同原因血小板减少症患者促血小板生成素和血清白细胞介素-11水平的检测及意义

详细信息
  • 中图分类号: R558

Measurement of serum thrombopoietin levels and serum interlukin-11 levels in patients with thrombocytopenia with different causes and its significance

  • 目的:探讨血小板减少症患者血清促血小板生成素(TPO)和白细胞介素-11(IL-11)水平及其与外周血小板计数之间的关系。方法:141例患者分为ITP组、血液肿瘤组和实体肿瘤组3组,应用双抗夹心ABC-ELISA法测定TPO、IL-11,同时用自动血细胞仪测定其血小板数,以30 例健康人为正常对照。结果:ITP组、血液肿瘤组和实体肿瘤组的血清TPO水平分别为(130.5±88.3)pg/ml、(103.5±83.9)pg/ml和(148.1±92.5)pg/ml,各组与对照组比较差异无统计学意义。ITP组、血液肿瘤组和实体肿瘤组的血清IL-11水平分别为(46.8±35.8)pg/ml、(40.3±24.7)pg/ml和(44.5±22.3)pg/ml;对照组则为(36.0±18.7)pg/ml。ITP组和实体肿瘤组血清IL-11水平明显高于对照组(均P<0.05)。结论:不同原因血小板减少症患者血清TPO、IL-11水平不一致,检测其有助于了解不同原因血小板减少的可能机制和指导临床治疗。
  • 加载中
  • [1]

    KAUSHANSKY K.Thrombopoietin:the primary regulator of platelet production[J].Blood,1995,86:419-419.

    [2]

    AYARA Y,SHOZAKI Y,NAGAHISA H,et al.Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platet during thrombocytopenia and thrombocytopenia and thrombocytosis[J].Thromb Haemost,1997,77:808-814.

    [3]

    HILL G R,FERRARA J L.The primacy of the gastrointestional tract as atarget organ of acute graft versus host disease:rationale for the use of cytokine shields in allogeneicbone marrow tran splantion[J].Blood,2000,95:2754-2759.

    [4]

    CHANG M,SUEN Y.Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia:insight into the regulation of platelet production[J].Blood,1996,88:3354-3362.

    [5]

    CREMER M,SCHULZE H,LINTHORST G,et al.Serum levels of thrombopoietin,IL-11,and IL-6 in pediatric thrombocytopenias[J].Ann Hematol,1999,78:401-407.

    [6]

    许冰莹,尚学琴,杨玲,等.ITP患者促血小板生成素水平和白细胞介素-11水平的检测及意义[J].昆明医学院学报,2006,27(5):550-551.

    [7]

    WU Y X,WANG H Y,WANG W,et al.Measurement and clinical significance of serum TPO and LDH levels in patients with myelodysplastic syndrome and acute leukemia[J].Zhongguo Shi Yan Xue Ye Xue Za Zhi,2010,18:671-674.

    [8]

    任明强,陈琦.多发性骨髓瘤血清TPO水平动态监测及临床意义[J].遵义医学院学报,2006,29(2):122-123.

    [9]

    王开泰,陆红娟,王天舒,等.血液肿瘤化疗后可溶性白细胞介素-11水平的变化及其意义[J].白血病·淋巴瘤,2009,18(5):287-289.

  • 加载中
计量
  • 文章访问数:  313
  • PDF下载数:  147
  • 施引文献:  0
出版历程
收稿日期:  2011-05-03
修回日期:  2011-11-03

目录